Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182661 | 0.84 | SLC6A4 (0.33) | SLC6A4ALOX5MAPT | |
| SCHEMBL7089384 | 0.80 | ALDH1A1 (0.39) | ALOX5KDM4EALDH1A1MAPT | |
| SCHEMBL4811110 | 0.79 | KDM4E (0.38) | ALOX5KDM4EHPGDALDH1A1MAPT | |
| SCHEMBL28563394 | 0.79 | ESR1 (0.48) | KDM4ETSHRALDH1A1MAPTSLC6A2 | |
| SCHEMBL4671383 | 0.79 | ALDH1A1 (0.40) | TSHRALDH1A1MAPT | |
| SCHEMBL7575011 | 0.79 | LMNA (0.39) | SLC6A4USP2HPGDALDH1A1SLC6A2 | |
| SCHEMBL16094149 | 0.79 | CYP19A1 (0.41) | TSHRALDH1A1 | |
| SCHEMBL6718841 | 0.79 | LMNA (0.39) | SLC6A4USP2HPGDALDH1A1SLC6A2 | |
| SCHEMBL3295316 | 0.78 | TRPA1 (0.42) | KDM4EHPGDTSHRALDH1A1MAPT | |
| SCHEMBL2610138 | 0.78 | TRPA1 (0.42) | KDM4EHPGDTSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | SLC6A4 2737/4885ALOX5 74/4885ACACB 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.